Benadryl

(Diphenhydramine)

ApprovedSmall molecule

Diphenhydramine is used to relieve allergy symptoms like itching, sneezing, and runny nose, and it also helps people fall asleep by causing drowsiness.[2] Benadryl is currently approved and in use across 66 indications[4].[1]

Benadryl is one of 1421 small molecule programs targeting Total Joint Arthroplasty. It is currently in Approved.

Indications

135

Total Trials

Active Trials

1,420

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

Total Joint ArthroplastyActive, not recruiting

Systemic Lupus ErythematosusActive, not recruiting

Neuropathic PainActive, not recruiting

Peripheral VertigoActive, not recruiting

Depressive DisorderApproved

Wound HealingActive, not recruiting

Migraine DisorderApproved

Liver TransplantActive, not recruiting

Kidney CancerActive, not recruiting

Aphthous UlcerApproved

Total Joint ArthroplastyApproved

Active, not recruiting

Systemic Lupus ErythematosusPhase 3

Active, not recruiting

Neuropathic PainPreclinical

Active, not recruiting

Peripheral VertigoPreclinical

Active, not recruiting

Depressive DisorderApproved

Approved

Wound HealingPreclinical

Active, not recruiting

Migraine DisorderApproved

Approved

Liver TransplantPhase 1

Active, not recruiting

Kidney CancerPhase 2

Active, not recruiting

Aphthous UlcerApproved

Approved

Showing 10 of 63 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Benadryl

PParkedale

Approved

1 2

Adriamycin

GGynecologic Oncology Group

Preclinical

87 3

Gemzar

GGynecologic Oncology Group

Preclinical

22 4

Cymbalta

Alnylam Pharmaceuticals

Preclinical

3 5

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 6

Recentin

NNational Cancer Institute (NCI)

Preclinical

2 7

Acupan

YYonsei University

Preclinical

1 8

Nubain

AAultman Health Foundation

Preclinical

1 9

Paracetamol

GSK

Preclinical

1 10

Neoadjuvant Treatment

SShanghai Zhongshan Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

N/AActive, not recruiting

Study completion

NCT00961792

Phase 2Active, not recruiting

Phase II

NCT05285813

Q1 2027

Phase 2Recruiting

Pathophysiology

NCT04862221

Phase 2Active, not recruiting

Multiple Myeloma

NCT04268498

Phase 3Active, not recruiting

Dexamethasone

NCT05405166

Q3 2027

Phase 2Recruiting

Multiple Myeloma

NCT06356571

Clinical

Trials by Indication[1]

Multiple Myeloma7 trials

Melphalan on Disease Burden Measured by Next Generation Sequencing Before AHCT (Autologous Hematopoietic Cell Transplant) for Multiple Myeloma

Withdrawn·KKoen van Besien·Phase 1·NCT05013437

A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma

Recruiting· Sanofi logo

Sanofi·Phase 2·NCT06356571·64 enrolled

An Efficacy and Safety Study of Daratumumab in Patients With Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor [PI] and Immunomodulatory Drug [IMiD]) or Are Double Refractory to a PI and an IMiD

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 2·NCT01985126·124 enrolled

Show 4 more trials

A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma

Active, not recruiting· Sanofi logo

Sanofi·Phase 2·NCT05704049·118 enrolled

A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT01998971·240 enrolled

A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma

Active, not recruiting·UUniversity of Miami·Phase 2·NCT04268498·310 enrolled

Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma

Recruiting·—·Phase 2·NCT05896228·30 enrolled

Headache5 trials

Metoclopramide for Post Traumatic Headache

Completed·MMontefiore Medical Center·Phase 3·NCT03220958·160 enrolled

Metoclopramide for Post-Traumatic Headache. A Pilot Study

Completed·MMontefiore Medical Center·Phase 1/2·NCT03056352·21 enrolled

The CHECK Trial: A Comparison of Headache Treatment in the ED: Compazine Versus Ketamine

Completed·UUniversity Medical Center of Southern Nevada·Phase 4·NCT02657031·54 enrolled

Show 2 more trials

Efficacy of Haloperidol vs. Metoclopramide for Treatment of Acute Headaches and Migraines in the Emergency Department

Terminated·OOhioHealth·Phase 4·NCT02972502·66 enrolled

Haldol/Diphenhydramine Versus Metoclopramide/Diphenhydramine for Treatment of Acute Headache in the ED: A RCT

Withdrawn·UUnited States Naval Medical Center, Portsmouth·Phase 4·NCT02098499

Migraine4 trials

Hydromorphone Versus Prochlorperazine + Diphenhydramine for Acute Migraine

Completed·MMontefiore Medical Center·Phase 4·NCT02389829·127 enrolled

Diphenhydramine for Acute Migraine

Completed·MMontefiore Medical Center·Phase 4·NCT01825941·208 enrolled

Intravenous Fluids in Pediatric Migraine

Unknown status·—·N/A·NCT06182098·134 enrolled

Show 1 more trial

Metoclopramide for Migraine: A Dose Finding Study

Completed·MMontefiore Medical Center·Phase 3·NCT00682734·349 enrolled

Tics3 trials

A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986263 in Healthy Participants

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT03142165·33 enrolled

First-time-in-man, to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BP1.5375

Terminated·BBioprojet·Phase 1·NCT01965301·48 enrolled

A Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7283420.

Completed· Roche logo

Roche·Phase 1·NCT04580121·59 enrolled

Lupus Nephritis3 trials

A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With ISN/RPS 2003 Class III or IV Lupus Nephritis

Active, not recruiting· Roche logo

Roche·Phase 3·NCT04221477·271 enrolled

Rituximab and Belimumab for Lupus Nephritis

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT02260934·43 enrolled

A Study to Evaluate the Efficacy and Safety of Rituximab in Subjects With International Society of Nephrology/Renal Pathology Society (ISN/RPS) 2003 Class III or IV Lupus Nephritis

Completed· Roche logo

Roche·Phase 3·NCT00282347·144 enrolled

96 more indications

Systemic Lupus Erythematosus3 trials

A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus

Terminated· Roche logo

Roche·Phase 3·NCT00381810·31 enrolled

A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus

Completed· Roche logo

Roche·Phase 2/3·NCT00137969·262 enrolled

Lymphocyte Depletion and Stem Cell Transplantation to Treat Severe Systemic Lupus Erythematosus

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00076752·9 enrolled

Kidney Transplant3 trials

Treg Therapy in Subclinical Inflammation in Kidney Transplantation

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1/2·NCT02711826·32 enrolled

Effects of Inhibiting Early Inflammation in Kidney Transplant Patients

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT02495077·290 enrolled

Combination Immunosuppressive Therapy to Prevent Kidney Transplant Rejection in Adults

Completed·UUniversity of Wisconsin, Madison·Phase 1/2·NCT00078559·10 enrolled

Gastric Adenocarcinoma2 trials

Study of Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT03330028·29 enrolled

A Phase II Study of Perioperative Paclitaxel in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT05977998·30 enrolled

Urticaria2 trials

Pilot Phase III Clinical Trial of JDP-205 IV Injection for Treatment of Acute Urticaria

Completed·JJDP Therapeutics, Inc.·Phase 3·NCT02023164·36 enrolled

Using Doxepin for Urticaria

Unknown status·SState University of New York - Upstate Medical University·Phase 3·NCT05115136·160 enrolled

TED2 trials

Study of Ramucirumab (IMC-1121B) Therapy and Corrected QT (QTc) Interval Changes

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT01017731·68 enrolled

Comparing Risk and Severity of IRRs in Patients Premedicated With Cetirizine vs. Diphenhydramine Prior to Ocrelizumab

Completed·PProvidence Health & Services·Phase 3·NCT04175834·19 enrolled

Non-Small Cell Lung Cancer2 trials

Study of Tislelizumab and Platinum-based Chemotherapy Combination With H1 Receptor Antagonist（Diphenhydramine）in Advanced and Metastatic Non-Small Cell Lung Cancer

Not yet recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 3·NCT06704620·430 enrolled

Toripalimab Combined With Platinum-based Chemotherapy With or Without H1 Receptor Antagonist in the Perioperative Treatment of Resectable Non-small Cell Lung Cancer

Not yet recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT07358689·120 enrolled

Driving2 trials

Study to Assess the Effect of Gabapentin Enacarbil on Simulated Driving in Healthy Subjects

Completed·XXenoPort, Inc.·Phase 1·NCT01411124·36 enrolled

A Study of Lasmiditan on Simulated Driving Performance in Healthy Participants

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT03459612·68 enrolled

Chronic Idiopathic Urticaria2 trials

A Safety Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic Despite Treatment With H1 Antihistamines, H2 Blockers, and/or Leukotriene Receptor Antagonists

Completed· Roche logo

Roche·Phase 3·NCT01264939·336 enrolled

A Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic With Antihistamine Treatment (H1)

Completed· Roche logo

Roche·Phase 2·NCT00866788·90 enrolled

Leukemia2 trials

Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia

Terminated·SSt. Jude Children's Research Hospital·Phase 2·NCT03913559·5 enrolled

Safety and Efficacy of Isatuximab in Lymphoblastic Leukemia

Terminated· Sanofi logo

Sanofi·Phase 2·NCT02999633·14 enrolled

Morphine2 trials

Evaluation of Peripheral Itch Mechanisms Following Injection of Morphine (Second Sub-Project)

Completed·—·N/A·NCT04700007·26 enrolled

Study To Assess The Effect Of Gabapentin, Diphenhydramine And Morphine On Cold Pain In Healthy Male Volunteers

Completed· Pfizer logo

Pfizer·Phase 1·NCT01119222·19 enrolled

Prevention2 trials

Droperidol on Prevention of Cannabis Hyperemesis Syndrome

Unknown status·MMercy Health Ohio·Phase 3·NCT05244460·45 enrolled

Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD

Completed·SStanford University·Phase 2·NCT00186628·36 enrolled

Hairy Cell Leukemia2 trials

Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT01059786·69 enrolled

A Phase I Study of Moxetumomab Pasudotox-tdfk (Lumoxiti (TM)) and Either Rituximab (Rituxan (R)) or Ruxience for Relapsed Hairy Cell Leukemia

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT03805932·18 enrolled

Immunogenicity1 trial

Effect of Raxibacumab on Immunogenicity of Anthrax Vaccine Adsorbed

Completed· Emergent BioSolutions logo

Emergent BioSolutions·Phase 4·NCT02339155·573 enrolled

Oral Mucositis1 trial

Morphine Mouthwash for Management of Oral Mucositis in Patients With Head and Neck Cancer

Completed·IIsfahan University of Medical Sciences·Phase 2/3·NCT01837446·30 enrolled

Advanced Solid Cancers1 trial

An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of HLX07,in Patients With Advanced Solid Cancers

Completed·HHenlix, Inc·Phase 1·NCT02648490·19 enrolled

Sickle Cell Disease1 trial

Abatacept for GVHD Prophylaxis After Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease

Completed·MMonica Bhatia·Phase 1·NCT02867800·24 enrolled

Pathophysiology1 trial

TReatment for ImmUne Mediated PathopHysiology

Recruiting·NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 2·NCT04862221·163 enrolled

HPV Associated Cancers1 trial

HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1/2·NCT04432597·39 enrolled

Fusion Rate1 trial

A Study of ARC-520 at Varying Infusion Rates in Healthy Adult Volunteers

Completed· Arrowhead Pharmaceuticals logo

Arrowhead Pharmaceuticals·Phase 1·NCT02535416·40 enrolled

Follicular Lymphoma1 trial

A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT06043323·20 enrolled

Pompe Disease1 trial

Re-administration of Intramuscular AAV9 in Patients With Late-Onset Pompe Disease

Completed·UUniversity of Florida·Phase 1·NCT02240407·2 enrolled

Postoperative Pain Control1 trial

Post Operative Pain Control After Pediatric Hip Surgery

Terminated·SSeattle Children's Hospital·N/A·NCT03435692·42 enrolled

Outcome1 trial

Lumbar Stenosis Outcomes Research (LUSTOR)

Completed·UUniversity of Rochester·Phase 4·NCT00638443·29 enrolled

Transplantation1 trial

Phase 2 Study of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using TLI & ATG

Completed·SStanford University·Phase 2·NCT00899847·9 enrolled

Chronic Hepatitis1 trial

Study of ARC-520 in Participants With Hepatitis B Virus e Antigen (HBeAg) Positive Chronic Hepatitis B Virus

Terminated· Arrowhead Pharmaceuticals logo

Arrowhead Pharmaceuticals·Phase 2·NCT02452528·4 enrolled

Small Cell Lung Cancer1 trial

M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT03554473·37 enrolled

Dexamethasone1 trial

SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM

Active, not recruiting· Sanofi logo

Sanofi·Phase 3·NCT05405166·531 enrolled

Vertigo1 trial

Treating Benign Paroxysmal Positional Vertigo (BPPV) in ED Patients

Completed·LLehigh Valley Hospital·N/A·NCT00641797·26 enrolled

Alcohol Dependence1 trial

A Double-Blind Trial of Psilocybin-Assisted Treatment of Alcohol Dependence

Completed·NNYU Langone Health·Phase 2·NCT02061293·95 enrolled

B-cell Malignancies1 trial

Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT04599634·11 enrolled

Stem Cell Transplantation1 trial

Stem Cell Transplantation in Crohn's Disease

Recruiting·—·Phase 1/2·NCT04224558·15 enrolled

Caesarean Section1 trial

Intrathecal Levobupivacaine With Opioids for Caesarean Section

Completed·—·Phase 3·NCT01858090·93 enrolled

Pregnancy1 trial

A Cost Effective Treatment for Headache in Pregnancy When Acetaminophen Alone is Ineffective.

Completed·SSt. Louis University·N/A·NCT02295280·70 enrolled

Tolerance1 trial

BMT and High Dose Post-Transplant Cyclophosphamide for Chimerism Induction and Renal Allograft Tolerance

Terminated·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT02029638·4 enrolled

Malignant Mesothelioma1 trial

Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT04840615·2 enrolled

Metastatic Prostate Cancer1 trial

Impact of Temsirolimus Therapy on Circulating Tumor Cell Biology In Men With Castration Resistant Metastatic Prostate Cancer

Terminated·—·Phase 2·NCT00887640·11 enrolled

Endoscopic Retrograde Cholangiopancreatography (ERCP)1 trial

Adjunct Sedatives in Endoscopic Ultrasound (EUS) and Endoscopic Retrograde Cholangiopancreatography (ERCP) Procedures

Completed·UUniversity of California, Irvine·Phase 4·NCT00937924·304 enrolled

Ketorolac1 trial

Intranasal Ketorolac Trial

Terminated·WWashington University School of Medicine·Phase 2·NCT06083571·41 enrolled

Restless Legs Syndrome1 trial

Simulated Driving Study in Restless Legs Syndrome

Completed·XXenoPort, Inc.·Phase 2·NCT01332318·130 enrolled

Phase 21 trial

Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT

Terminated·SStanford University·Phase 2·NCT00482053·3 enrolled

Local Anesthesia1 trial

Lidocaine Versus Diphenhydramine to Achieve Local Anesthesia for Laceration Repairs

Recruiting·—·Phase 3·NCT06910241·100 enrolled

Lymphoma1 trial

Tailoring Treatment for B Cell Non-hodgkin's Lymphoma Based on PET Scan Results Mid Treatment

Unknown status·BBritish Columbia Cancer Agency·Phase 2·NCT00324467·150 enrolled

Head and Neck Cancer1 trial

Chemotherapy and Locoregional Therapy Trial (Surgery or Radiation) for Patients With Head and Neck Cancer

Completed·UUniversity of Chicago·Phase 2·NCT03107182·72 enrolled

Lenalidomide1 trial

Effect of P-glycoprotein Inhibition on Lenalidomide Pharmacokinetics in Healthy Males

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT01712828·31 enrolled

Emergency Department Patient1 trial

Ketamine as a Rapidly-Acting Antidepressant in Depressed Emergency Department Patients

Completed·NNYU Langone Health·Phase 2·NCT02106325·21 enrolled

Neuropathic Pain1 trial

The Role of Intravenous (IV) Lidocaine in the Management of Chronic Neuropathic Pain of Peripheral Nerve Origin

Completed·LLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's·N/A·NCT01669967·34 enrolled

Diffuse Large B-Cell Lymphoma1 trial

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (VIPOR) for Diffuse Large B-cell Lymphoma Involving the Central Nervous System

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT05211336·14 enrolled

Preoperative1 trial

Preoperative Gabapentin for Acute and Chronic Post-thoracotomy Analgesia

Completed·MMichelle Kinney·N/A·NCT00588159·146 enrolled

Chronic1 trial

Diphenhydramine as an Adjunctive Sedative in Patients on Chronic Opioids

Completed·UUniversity of Oklahoma·Phase 4·NCT01967433·120 enrolled

Lung Cancer1 trial

TUSC2-nanoparticles and Erlotinib in Stage IV Lung Cancer

Terminated·GGenprex, Inc.·Phase 1/2·NCT01455389·25 enrolled

Adenocarcinoma1 trial

A Phase I/II Study of Intraperitoneal Paclitaxel in Patients With Metastatic Appendiceal Adenocarcinoma

Recruiting·MM.D. Anderson Cancer Center·Phase 1/2·NCT06207305·39 enrolled

Phase II1 trial

A Phase II Study of Vibecotamab (XmAb14045) for MRD- Positive AML and MDS After Hypomethylating Agent Failure

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT05285813·42 enrolled

Advanced Malignant Solid Tumors1 trial

Evaluation of SAR408701 in Japanese Patients With Advanced Malignant Solid Tumors

Completed· Sanofi logo

Sanofi·Phase 1·NCT03324113·34 enrolled

COVID-191 trial

Intermediate-size Expanded Access Program (EAP), Mesenchymal Stromal Cells (MSC) for Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19)

No longer available·MMesoblast International Sàrl··NCT04456439

Allogeneic Hematopoietic Cell Transplant1 trial

Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT02356159·34 enrolled

Morbidity1 trial

A Policy Relevant US Trauma Care System Pragmatic Trial for PTSD and Comorbidity

Completed·UUniversity of Washington·N/A·NCT02655354·635 enrolled

Peripheral Vertigo1 trial

Sodium Bicarbonate for Acute Peripheral Vertigo

Unknown status·NNational Taiwan University Hospital·N/A·NCT05676216·225 enrolled

Recurrent or Refractory1 trial

CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT03448393·54 enrolled

Prospective1 trial

A Prospective Study to Investigate Safety and Tolerability of Shorter Infusion of Fabrazyme

Completed· Sanofi logo

Sanofi·Phase 4·NCT06019728·8 enrolled

Clinical Trial1 trial

Feasibility of a Clinical Trial Comparing the Use of Cetirizine to Replace Diphenhydramine in the Prevention of Reactions Related to Paclitaxel

Completed·CCiusss de L'Est de l'Île de Montréal·Phase 3·NCT04237090·27 enrolled

Vaccine1 trial

Wilm's Tumor 1 Protein Vaccine to Treat Cancers of the Blood

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT00923910·10 enrolled

Acute Mountain Sickness1 trial

Efficacy of Prophylactic Treatment of Oral Prochlorperazine for Acute Mountain Sickness

Completed·CCHRISTUS Health·Phase 4·NCT06310642·30 enrolled

Atopic Dermatitis1 trial

Treatment of Nighttime Pruritus in Atopic Dermatitis

Withdrawn·UUniversity of Nebraska·Phase 1·NCT03688464

Hyperalgesia1 trial

Study on the Development of Opioid Induced Hyperalgesia (OIH) After Exposure to Alfentanil

Completed·JJohns Hopkins University·N/A·NCT00991809·22 enrolled

Kidney Cancer1 trial

BMS 247550 to Treat Kidney Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00030992·102 enrolled

Alpha-1 Antitrypsin Deficiency1 trial

A Study of ARC-AAT in Healthy Volunteer Subjects and Patients With Alpha-1 Antitrypsin Deficiency (AATD)

Terminated· Arrowhead Pharmaceuticals logo

Arrowhead Pharmaceuticals·Phase 1·NCT02363946·65 enrolled

Side Effects1 trial

Pharmacogenetic Factors and Side Effects of Metoclopramide and Diphenhydramine

Terminated·MMatthias Schwab·Phase 1·NCT01289938·49 enrolled

Breast Cancer1 trial

Safely Stopping Pre-medications in Patients With Breast Cancer Who Are Receiving Paclitaxel

Completed·OOhio State University Comprehensive Cancer Center·Phase 2/3·NCT04862585·130 enrolled

Intraperitoneal Chemotherapy1 trial

A Phase II Trial of Neoadjuvant Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) With Chemoradiation

Unknown status·IIcahn School of Medicine at Mount Sinai·Phase 2·NCT04308837·29 enrolled

Children1 trial

Rescue Emetic Therapy for Children Having Elective Surgery

Withdrawn·FFranklyn Cladis·N/A·NCT01067677

Nasal congestion1 trial

To Determine if Diphenhydramine Works for Nasal Congestion at Two Different Doses

Completed·JJohnson & Johnson Consumer and Personal Products Worldwide·Phase 4·NCT00648973·1,021 enrolled

Acute Lymphoblastic Leukemia1 trial

Anti-histamines and Methacholine Challenges.

Completed·DDon Cockcroft·Phase 4·NCT01985789·12 enrolled

Serous Carcinoma1 trial

Papillary Serous Carcinoma of the Endometrium

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00515073·30 enrolled

Completed·UUniversity of Florida·Phase 2·NCT02142712·3 enrolled

Bulimia Nervosa1 trial

Neural Response to Catecholamine Depletion in Subjects Suffering From Bulimia Nervosa in Their Past and Healthy Controls

Suspended·UUniversity of Bern·N/A·NCT02179814·60 enrolled

Hyperuricemia1 trial

A Study Exploring Efficacy of Pegloticase in Subjects With Asymptomatic Hyperuricemia

Completed·SShanghai Institute Of Biological Products·Phase 1·NCT05302388·45 enrolled

Relapsed/Refractory1 trial

Phase 2 Study of Bexxar in Relapsed/Refractory DLCL

Completed·SSusan Knox·Phase 2·NCT00490009·9 enrolled

Liver Transplant1 trial

Donor-Alloantigen-Reactive Regulatory T Cell (darTregs) in Liver Transplantation

Terminated·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT02188719·15 enrolled

Psilocybin1 trial

Psilocybin-facilitated Treatment for Cocaine Use

Completed·UUniversity of Alabama at Birmingham·Phase 2·NCT02037126·40 enrolled

Pulmonary Arterial Hypertension1 trial

Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT01086540·57 enrolled

Agitation1 trial

Dyphenhidramine Effect on Prevention of Sevoflurane Induced Post Anesthesia Agitation in Pediatric

Completed·UUniversitas Diponegoro·Phase 4·NCT02463929·50 enrolled

Autism1 trial

Trial of Diphenhydramine for Sleep in Children With Autism

Recruiting·SStanford University·Phase 2·NCT05501678·26 enrolled

Major Depressive Disorder1 trial

A Safety, Efficacy and Biomarker Study of JNJ-42847922 in Participants With Major Depressive Disorder

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT02476058·48 enrolled

Colonoscopy1 trial

Randomized Trial of Diphenhydramine Versus Continued Midazolam in "Difficult-to-sedate" Patients Undergoing Colonoscopy

Completed·VVA Connecticut Healthcare System·N/A·NCT01769586·200 enrolled

Total Joint Arthroplasty1 trial

Total Joint Arthroplasty and Sleep

Completed·JJames A. Keeney·Phase 4·NCT03968939·55 enrolled

Wound Healing1 trial

Post Burn Pruritus Study in Patients Undergoing Wound Healing

Completed·UUnited States Army Institute of Surgical Research·N/A·NCT00137202·36 enrolled

Central Nervous System1 trial

Central Nervous System Effects Following Infusion of Diphenhydramine Using Pharmacokinetic and Pharmacodynamic Modeling

Terminated·—·Phase 4·NCT05219604·3 enrolled

Stress1 trial

Over-the-Counter Antihistamines & Heat Stress

Unknown status·LLakehead University·Phase 4·NCT06217367·16 enrolled

Multiple Sclerosis1 trial

Cetirizine Versus Diphenhydramine as a Pre-medication: Tolerability and Safety in Patients With MS Receiving Anti-Cluster of Differentiation 20 (CD20) Infusion Therapy

Not yet recruiting·UUniversity of Miami·Phase 3·NCT07472413·60 enrolled

B-cell acute lymphoblastic leukemia1 trial

A Phase 2/3, Randomized, Open-Label, Comparison Study of MK-1045 Versus Blinatumomab in Participants With Relapsed or Refractory CD19+ B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Recruiting· Merck & Co. logo

Merck & Co.·Preclinical·NCT07570173·340 enrolled

Primary Membranous Nephropathy1 trial

A Phase III Randomized, Open-Label Active Comparator-Controlled Multicenter Study to Evaluate Efficacy and Safety of Obinutuzumab in Patients With Primary Membranous Nephropathy

Active, not recruiting· Roche logo

Roche·Phase 3·NCT04629248·142 enrolled

Carcinoma, Non-Small-Cell Lung1 trial

KEYMAKER-U01 Substudy 3: A Phase 2, Umbrella Study With Rolling Arms of Investigational Agents in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Previously Treated With Anti-PD-(L)1 Therapy

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT04165096·128 enrolled

Schizophrenia1 trial

EMERGE-3: KarXT in Acute Schizophrenia

Active, not recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT04681105·580 enrolled

Unspecified4 trials

Chicago Social Drinking Project

Active, not recruiting·UUniversity of Chicago·N/A·NCT00961792·800 enrolled

Pharmacovigilance in Gerontopsychiatric Patients

Terminated·HHannover Medical School·Phase 3·NCT02374567·407 enrolled

Diphenhydramine and Sweating

Completed·LLakehead University·Phase 4·NCT05586477·20 enrolled

Show 1 more trial

The Montefiore Metoclopramide Study

Completed·MMontefiore Medical Center·Phase 4·NCT00475306·289 enrolled

Regulatory

FDA Approval Timeline[5]

Jan 1, 1982

BENADRYL

NDA NDA005845

Jan 1, 1982

BENADRYL

NDA NDA006146

Jan 1, 1982

BENADRYL PRESERVATIVE FREE

NDA NDA009486

Jan 1, 1982

BENYLIN

NDA NDA006514

Sources

References

[1]
ClinicalTrials.gov — 135 trial records for Diphenhydramine. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Benadryl drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Diphenhydramine compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Diphenhydramine. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA005845). U.S. Food & Drug Administration.
[6]
SEC EDGAR — Parkedale company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Histamine H1 Receptor Antagonist[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: PParkedale